1 tracked superinvestor hold Monte Rosa Therapeutics Inc (GLUE), worth $7M combined, led by Stanley Druckenmiller. Smart money is accumulating GLUE as of the latest 13F filings.
Current price
$13.84
+181.9%
1Y
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and…
Market cap
$1.2B
P/E
-40.87
Div yield
0.0%
Revenue YoY
63.5%
Analyst target
$27
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$7M
disclosed long exposure
Tier-1 conviction
1
concentrated holders
Net this quarter
+1
1 buying · 0 selling
Smart money is net accumulating GLUE: 1 funds added or opened versus 0 trimming. 1 opened a brand-new position.
Monte Rosa Therapeutics Inc (GLUE) is held by 1 tracked funds worth $7M combined, 1 of them concentrated Tier-1 managers whose positions carry real conviction.
The largest position belongs to Stanley Druckenmiller at 0.1% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
This quarter 1 fund opened a brand-new position (Stanley Druckenmiller), with 0 adding and 0 trimming — a net accumulation signal.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| New buy | 0.1% | $7M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
Which superinvestors own GLUE?
1 tracked funds hold Monte Rosa Therapeutics Inc (GLUE), the largest being Stanley Druckenmiller (Duquesne Family Office) at 0.1% of its 13F portfolio. 1 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling GLUE?
In the most recent 13F quarter, 1 tracked fund added or opened GLUE and 0 trimmed it, including 1 brand-new position.
How much GLUE do tracked funds hold?
Combined disclosed long exposure to GLUE across tracked superinvestors is $7M as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.